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BACKGROUND/OBJECTIVES: Randomized controlled
trials are used to inform clinical guidelines on the manage-
ment of hypertension in older adults, but it is unclear to
what extent these trials represent the general population
attending routine clinical practice. This study aimed to
define the proportion and characteristics of patients eligible
for hypertension trials conducted in older people.
DESIGN: Cross-sectional study.
SETTING: A total of 24 general practices in England.
PARTICIPANTS: Anonymized electronic health record
data from all individuals aged 80 and older.
MEASUREMENTS: Descriptive statistics were used to
define the proportion and characteristics of patients eligible
for two previous medication intensification trials (HYVET,
SPRINT) and one medication reduction trial (OPTiMISE).
A logistic regression model was constructed to estimate pre-
dictors of eligibility for each trial.
RESULTS: Of 15,376 patients identified, 268 (1.7%;
95% confidence interval [CI] = 1.5–2.0%), 5,290 (34.4%;
95%CI = 33.7–35.2%), and 3,940 (25.6%; 95%CI =
24.9–26.3%) were eligible for the HYVET, SPRINT, and
OPTiMISE trials, respectively. Between 5.6% and 30.7% of
exclusions from each trial were due to eligibility criteria
excluding those with high or uncontrolled blood pressure.
Frailty (odds ratio [OR] = .44; 95%CI = .36–.54 [OPTi-
MISE]), cardiovascular polypharmacy (OR = .61; 95%
CI = .55–.68 [SPRINT]) and multimorbidity (OR = .72;
95%CI = .64–.82 [SPRINT]) were associated with a lower
likelihood of being eligible for one or more of the trials.
CONCLUSION: A possible unintended consequence of
blood pressure criteria used by trials attempting to answer
different primary questions is that for many older patients,
no trial evidence exists to inform treatment decisions in rou-
tine practice. Caution should be exercised when applying
results from existing trials to patients with frailty or mul-
timorbidity. J Am Geriatr Soc 00:1-8, 2020.
Keywords: hypertension; cardiovascular disease; frailty;
electronic health records; randomized controlled trials
Hypertension is a major modifiable risk factor for car-diovascular disease (CVD),1 and an individual’s risk
of a cardiovascular event can be significantly reduced with
treatment to lower blood pressure.2 In older individuals
aged 80 and older, previous trials showed benefit with
treatment,3,4 although meta-analyses of these and other
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trials indicated that larger blood pressure reductions and
multiple antihypertensive prescriptions may also be
harmful.5,6 Observational studies also suggested that
blood pressure lowering in older patients may be harmful,
particularly in patients with frailty and multimorbidity,
increasing the risk of falls,7 acute kidney injury,8 and
death.9,10
The two largest trials that have examined the efficacy
of antihypertensive treatment in patients aged 80 and older
are the Hypertension in the Very Elderly Trial (HYVET)3
and the Systolic Blood Pressure Intervention Trial
(SPRINT).4 HYVET showed in patients with a baseline sys-
tolic blood pressure of 160 mm Hg and higher that blood
pressure lowering to a target of 150 mm Hg systolic reduces
the risk of CVD, heart failure, and death from any cause.3
The SPRINT trial showed that in patients with a baseline
systolic blood pressure of 130 mm Hg and higher, systolic
blood pressure lowering to 120 mm Hg (defined using auto-
mated and mostly unaccompanied measurement methods)
reduced the risk of CVD and death,4 and this effect was
sustained in a subgroup of participants aged 80 and older,
although not in those with reduced cognitive function.11
However, it is unclear to what extent these results apply
to older patients in routine practice,12,13 particularly with
population-wide observational data suggesting treatment
may be harmful.7-9 Indeed, patients in the HYVET trial are
thought to have had fewer comorbidities,14 whereas it is
unclear to what extent the levels of frailty observed in the
SPRINT population15 compared with those in the general
populations of Europe and North America.16,17
The 2018 Optimizing Treatment for Mild Systolic
Hypertension in the Elderly (OPTiMISE) trial examined the
safety of reducing blood pressure medications in older
patients with controlled systolic blood pressure (<150 mm
Hg).18 The rationale for OPTiMISE was that patients with
frailty and multimorbidity are not well represented in previ-
ous blood pressure lowering trials and may in fact benefit
from fewer treatments, due to a reduction in adverse events
from polypharmacy.19,20 The present study aimed to examine
this rationale by (1) determining the proportion of patients
registered at a primary care practice who would be eligible
for each of the HYVET, SPRINT, and OPTiMISE trials;
(2) establishing what patient characteristics are associated
with being eligible, and (3) comparing the characteristics of
patients in the participating practices who would have been
eligible for the trials with those actually enrolled in each trial.
METHODS
Detailed methods are given in the Supplementary Methods
S1 (Supplementary Appendix).
Study Design
This study used a cross-sectional design, utilizing ano-
nymized data extracted from the medical records of patients
registered at general practices enrolled in the OPTiMISE
trial.18 Data were extracted between September 2017 and
October 2018 using Egton Medical Information Systems
(EMIS) search and reporting software (Egton Medical Infor-
mation Systems Health, Leeds, UK). The study was
approved by a National Health Service Research Ethics
Committee (South Central-Oxford A; ref 16/SC/0628).
Because data were fully anonymized, no individual patient
consent was required.
Population
Eligible patient data were those from individuals aged
80 and older and registered at English general practices
hosting the OPTiMISE trial. General practices had to be
using the EMIS electronic health record system and agree to
anonymized patient data being extracted for the study.
Study Outcomes
The primary outcome for the study was the proportion of
patients in the participating practices who would have been
eligible for the HYVET, SPRINT, and OPTiMISE trials.
These trials were chosen because they represent the largest
trials conducted to date examining hypertension manage-
ment strategies (both prescribing and deprescribing) in older
adults. Secondary outcomes were to describe the character-
istics of eligible patients, to determine the proportion of
individuals excluded by each eligibility criteria, and to iden-
tify independent predictors of eligibility. The characteristics
of those eligible in the participating practices were com-
pared with those enrolled in each trial. Patients were classi-
fied as eligible if they fulfilled the published inclusion and
exclusion criteria for each trial (Table 1). Due to the use of
data from electronic health records, it was not possible to
apply some eligibility criteria to the sample population
(Supplementary Table S1).
Covariates
Data relating to baseline patient characteristics (age, sex,
smoking status, and body mass index [BMI]), blood pres-
sure, cholesterol, comorbidities, and details of all prescribed
cardiovascular medications were extracted. A frailty index
(FI) was developed retrospectively from 26 available defi-
cits. Frailty was categorized using the thresholds reported in
the SPRINT trial: fit (FI <.1), less fit (FI .1–.21), and frail
(FI >.21). Cardiovascular polypharmacy was defined as
being prescribed three or more medications for cardiovascu-
lar conditions (eg, antihypertensive, statin, antiplatelet, or
diabetic medications).
To examine predictors of eligibility for each trial, miss-
ing data for blood pressure and BMI were assumed missing
at random and imputed using multiple imputation with
chained equations.21 Data on the characteristics of patients
actually enrolled in each trial were extracted from previous
publications (HYVET, SPRINT)3,11 or obtained from the
original trial data set (OPTiMISE).18
Main Analyses
Descriptive statistics were used to define the primary out-
come, the characteristics of eligible patients, and the propor-
tion of patients excluded by each eligibility criteria. To better
understand the phenotype of patients eligible for each trial, a
logistic regression model was constructed to examine predic-
tors of eligibility for each trial, with general practice (site)
included as a random effect. Candidate predictors for each
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model were prespecified as age, sex, blood pressure, BMI,
frailty, number of comorbidities, number of cardiovascular
medications, history of hypertension, chronic kidney disease,
diabetes mellitus, type II, myocardial infarction, stroke
(or transient ischemic attack), and heart failure or coronary
artery bypass graft. Comparisons between the characteristics
of eligible patients and those included in the original trials
were made using independent samples t tests and two sample
tests of proportions. Bonferroni correction was used to
account for multiple comparisons.
Sensitivity Analyses
The definition of clinic blood pressure (most recently
recorded reading) was examined in sensitivity analyses where
the blood pressure eligibility criteria for each trial were
defined according to the mean of the last three readings
documented in the medical records. Further analyses exam-
ined the proportion of patients with hypertension (defined by
a coded diagnosis or prescription of antihypertensive ther-
apy) who would have been eligible for each trial. For logistic
regression models examining predictors of eligibility, sensitiv-
ity analyses were undertaken based on complete cases only,
to establish the impact of using multiple imputations to deal
with missing data. Further sensitivity analyses were under-
taken on complete cases using a standard logistic regression
model with backward stepwise selection of candidate predic-
tors, with the significance level for inclusion set to P < .05.
All analyses were conducted using STATA v.14.1 (Special
Edition, StataCorp, College Station, TX).
Table 1. Eligibility Criteria for Each Triala
Covariate
Eligibility criteria applied
HYVET trial SPRINT trial (older subgroup) OPTiMISE trial
Age, y ≥80 ≥80 ≥80
Sex Male and female Male and female Male and female
Systolic blood pressure 160–199 mmHg 130–180 mm Hg
(0–1 meds), or
130–170 mm Hg
(2 meds), or
130–160 mm Hg
(3 meds), or
130–150 mm Hg
(4 meds)
<150 mm Hg (≥2 meds)
Diastolic blood pressure <110 mm Hg
Serum creatinine <150 μmoL/L
Dementia, secondary
hypertension, terminal illness
Exclude Exclude Exclude
Angina, IHD, ACS, VHD Exclude (if occurred in
past 3 mo)
Stroke or TIA Exclude Exclude (if occurred in past
12 mo)
Diabetes mellitus, type II,
proteinuria, PKD,
glomerulonephritis, organ
transplant
Exclude
Heart failure Exclude (congestive heart failure
with a diuretic or ACEi)
Exclude (if occurred in
past 6 mo)
Malignant hypertension Exclude Exclude
Left ventricular dysfunction Exclude (if only on ACEis/ARBs
and/or beta-blockers and/or
spironolactone)
Myocardial infarction Exclude (if occurred in
past 3 mo)
Exclude (if occurred in past
12 mo)
Orthostatic hypotension Exclude (standing SBP
<110 mm Hg)
Alcohol or drug abuse Exclude Exclude (if occurred in
past 12 mo)
In nursing home Exclude Exclude
Unintentional weight loss Exclude (if occurred in
past 6 mo)
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; HYVET, Hypertension in
the Very Elderly Trial; IHD, ischemic heart disease; OPTiMISE, Optimizing Treatment for Mild Systolic Hypertension in the Elderly [trial]; PKD, polycystic
kidney disease; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial; TIA, transient ischemic attack; VHD, valvular heart disease.
aApplied to data from electronic health records in this analysis.
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Figure 1. Proportion of patients eligible for each trial in the total population, those with cardiovascular disease and frailty. [Color
figure can be viewed at wileyonlinelibrary.com]
Figure 2. Proportion of patients excluded by each eligibility criteria (n = 15,376). DBP, diastolic blood pressure; SBP, systolic blood
pressure; SCr, serum creatinine; TIA, transient ischemic attack.
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RESULTS
Primary Results
Overall, 24 of 69 general practices participating in the OPTi-
MISE trial were using EMIS Health software and agreed to
provide data for this study. A total of 15,376 patients aged
80 and older were registered at these practices. Approxi-
mately 268 (1.7%; 95% confidence interval [CI] = 1.5–2.0%),
5,290 (34.4%; 95% CI = 33.7–35.2%), and 3,940 (25.6%;
95% CI = 24.9–26.3%) patients would have been eligible for
the HYVET, SPRINT, and OPTiMISE trials, respectively
(Figure 1). No patients were eligible for both HYVET and
OPTiMISE trials due to mutually exclusive blood pressure eli-
gibility criteria, but there was some overlap in eligibility for
HYVET and SPRINT, and SPRINT and OPTiMISE
(Figure 1). Having normal or controlled systolic blood pres-
sure was the most common reason for exclusion from each
trial, but up to one-third of patients with high or uncontrolled
blood pressure were also ineligible (HYVET = 30.7%;
SPRINT = 5.6%; OPTiMISE = 27.2%). Diagnosis of demen-
tia (12.6%), diabetes mellitus, type II (16.5% [SPRINT
only]), or stroke (14.6% [SPRINT only]) were other common
reasons for exclusion (Figure 2).
Sensitivity analyses examining blood pressure defined
as the mean of the last three recorded readings identified
similar proportions of patients eligible for each trial (data
available from authors). Similar proportions of patients
were eligible for each trial when the population was limited
to those with a previous diagnosis of hypertension, with the
exception of OPTiMISE that had more eligible hypertensive
patients (35.0%; 95% CI = 34.1–35.9%).
Characteristics of Eligible Patients
Patients eligible for each trial were similar in age and BMI,
but they had different levels of mean systolic blood pressure
(169  9 mm Hg [HYVET]; 141  10 mm Hg [SPRINT];
131  12 [OPTiMISE]; 132  16 mm Hg [general popula-
tion]), reflecting the different entry criteria. Patients eligible
for the HYVET and SPRINT trials had less frailty and mul-
timorbidity than those eligible for OPTiMISE (Table 2 and
Supplementary Table S3). The proportion of cardiovascular
Table 2. Characteristics of Patients Eligible and Enrolled to Each Trial
Characteristic
HYVET trial SPRINT trial OPTiMISE trial
Eligible
population
Reported
population3
P
valuea
Eligible
population
Reported
population11 P valuea
Eligible
population
Reported
population18
P
valuea
Patient characteristics
Total population 268 3,845 — 5,290 1,167 — 3,940 569 —
Age, y 85.6 83.6 < .001 85.0 83.5 < .001 84.8 84.8 1.000
Sex, % female 67.2 60.5 .097 61.5 38.7 < .001 58.0 51.5 .003
SBP, mm Hg 169.3 173.0 < .001 141.2 142.5 < .001 130.8 130.0 .134
DBP, mm Hg 81.2 90.8 < .001 75.6 70.0 < .001 71 69.3 < .001
BMI, kg/m2 26.6 24.7 < .001 26.4 27.1 < .001 27.7 27.6 .725
Frailty score: fit, % 50.8 — — 63.2 — — 31.0 22.3 < .001
Frailty score: less
fit, %
42.2 — — 33.9 — — 55.3 59.9 .038
Frailty score: frail, % 7.1 — — 2.9 — — 13.7 17.8 .008
Electronic frailty
index, median
.09 .16 — .09 — — .13 .14 —
Medical history, %
Hypertension 65.7 89.9 < .001 59.8 — — 89.4 96.1 < .001
Myocardial
infarction
8.2 3.1 < .001 4.4 — — 10.1 7.0 .019
Stroke/TIA 11.9 6.8 .001 .0 .0 — 13.0 7.9 < .001
CVD 28.0 11.8 < .001 17.3 27.2 < .001 42.4 30.4 < .001
Diabetes
mellitus, type II
14.6 6.8 < .001 .0 .0 — 23.0 17.8 .005
CKD 25.0 — — 22.5 50.6 < .001 36.8 32.7 .057
Prescribed medications, %
Antihypertensive 62.7 64.7 .508 61.4 — — 100.0 100.0 1.00
Statin 33.6 — — 32.1 50.7 < .001 61.0 33.2 < .001
Antiplatelet 25.4 — — 15.8 60.2 < .001 31.8 19.5 < .001
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HYVET, Hypertension in
the Very Elderly Trial; OPTiMISE, Optimizing Treatment for Mild Systolic Hypertension in the Elderly [trial]; SBP, systolic blood pressure; SPRINT, Systolic
Blood Pressure Intervention Trial; TIA, transient ischemic attack.
aData relating to the reported populations were extracted from previous publications (HYVET, SPRINT)3,11 or obtained from the original trial data set
(OPTiMISE).18 Comparisons were made using independent samples t tests and two sample tests of proportions. Standard deviations required for this analy-
sis are taken from the variance reported in the intervention arms of the original HYVET and SPRINT trials, giving conservative estimates of the difference
between groups. Bonferoni correction for significance level was P < .002.
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morbidities varied across trials, and the mean number of car-
diovascular medications was highest in patients eligible for
the OPTiMISE trial (Table 2 and Supplementary Table S3).
Predictors of Eligibility
Patients with higher systolic blood pressure were more
likely to be eligible for the HYVET and SPRINT trials
(odds ratio [OR] = 1.20; 95% CI = 1.18–1.22 [HYVET];
OR = 1.09; 95% CI = 1.09–1.10 [SPRINT]) but less likely
to be eligible for OPTiMISE (OR = .98; 95% CI = .97–.98),
again reflecting the opposing eligibility criteria for these tri-
als (Figure 3). Having frailty was associated with a lower
likelihood of being eligible for all trials (OR = .66; 95%
CI = .53–1.37 [HYVET]; OR = .09; 95% CI = .08–.12
[SPRINT]; and OR = .44; 95% CI = .36–.54 [OPTiMISE]).
The presence of cardiovascular polypharmacy and mul-
timorbidity were associated with lower odds of being eligi-
ble for the SPRINT trial (OR = .61; 95% CI = .55–.68
[polypharmacy]; OR = .72; 95% CI = .64–.82 [mul-
timorbidity]) but higher odds of being eligible for the OPTi-
MISE trial (OR = 14.67; 95% CI = 3.14–16.38
[polypharmacy]; OR = 1.16; 95% CI = .97–1.37 [mul-
timorbidity]). Results were similar in sensitivity analyses
examining complete cases only (Supplementary Figure S1).
Analyses using backward stepwise selection identified sys-
tolic blood pressure and reduced frailty as factors predicting
eligibility across all three trials (Supplementary Figure S2).
Eligible Patients Compared with Recruited Patients
Significant differences were found between those deemed eli-
gible in the present study and those recruited to each individ-
ual trial (Supplementary Table S3). Patients enrolled in the
HYVET trial were on average younger, with higher blood
pressure, lower BMI, and fewer cardiovascular morbidities
compared with the eligible population in the practices con-
sidered (P < .002). Patients in the SPRINT trial were also
younger, had lower diastolic blood pressure but higher sys-
tolic blood pressure, BMI, and more cardiovascular morbid-
ities and treatment (P < .001). Participants in the OPTiMISE
trial had lower diastolic blood pressure, and fewer had a his-
tory of stroke, CVD, or prescriptions for statin and anti-
platelet therapy than the total population that would have
been eligible (P < .001; Supplementary Table S3).
DISCUSSION
Summary of Main Findings
This study examined the characteristics of 15,376 patients
aged 80 and older registered in 24 general practices in
England. We found that most patients would not have been
eligible for randomized controlled trials that inform clinical
guidelines22-25 on the management of hypertension. Most of
the ineligibility related to the differing blood pressure eligibil-
ity criteria used by trials attempting to answer different pri-
mary questions, with up to a one-third of individuals with
Figure 3. Coefficient plot showing results of logistic regression analysis examining predictors of eligibility for each trial
(n = 15,376). aPolypharmacy defined as being prescribed three or more cardiovascular medications. BMI, body mass index; CABG,
coronary artery bypass graft; CI, confidence interval; DBP, diastolic blood pressure; eFI, electronic frailty index; OR, odds ratio;
SBP, systolic blood pressure; TIA, transient ischemic attack. [Color figure can be viewed at wileyonlinelibrary.com]
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high or uncontrolled blood pressure excluded. This is perhaps
not surprising. However, a possible unintended consequence
of these criteria was that eligible patients were less likely to
be frail and more likely to be prescribed multiple cardiovascu-
lar medications or have multimorbidity. Therefore, for many
older patients, no randomized controlled trials exist to
directly inform treatment decisions in routine practice.
Strengths and Weaknesses
This study examined data from a large sample of more than
15,000 patients registered to general practices across the
south-central region of England. Individuals were represen-
tative of the region and country in terms of age but may
not be reflective of practices in other parts of the country
that serve populations differing in ethnicity and social dep-
rivation.26 It is also possible that some selection bias may
have been present because only 24 of 69 practices
approached were able to participate.
The eligibility criteria that accounted for the largest
number of exclusions were those related to having high or
low systolic blood pressure. Our definition of systolic blood
pressure, based on the most recently recorded value, almost
certainly differs from the standardized readings taken in the
original trials.27 However, readings reflected routine practice,
and the same definition was used for each trial, and so com-
parisons between trials are still likely to be valid.
Our analyses were unable to consider the proportion
of eligible individuals who would likely give informed con-
sent to participate in each trial or the proportion deemed
in clinical equipoise by the treating physician. Indeed, in
the OPTiMISE trial, as few as 9% of those deemed poten-
tially eligible on the basis of information held in electronic
health records gave informed consent and were random-
ized, suggesting that these estimates are likely to be conser-
vative. Data presented in Table 2 suggest the decision to
participate may have been influenced by patient character-
istics such as sex, frailty, multimorbidity, and treatment
prescription. It was not possible to examine the associa-
tion between ethnicity and trial eligibility due to large
amounts of missing data in the electronic health records
for this patient characteristic.
Derivation of the FI was post hoc, and therefore some
of the deficits described in previous models were not
extracted from individual electronic health records.28 Of the
26 deficits available, each of the five domains that make up
a valid cumulative deficit frailty model were covered: signs,
symptoms, disease, disability, and abnormal laboratory
results.29 We therefore consider our frailty model to be valid.
Models used to define frailty in each of the previous trials
examined here were also derived post hoc and included a
wide variety of deficits (Supplementary Table S2).15,28,30 The
current analysis offered a unique opportunity to estimate
frailty and compare across trial-eligible populations using a
consistent definition.
Comparison with Previous Literature
A study from the Netherlands found that in a population of
patients attending a geriatric day clinic, less than one-half
would have been eligible for the HYVET trial, and those
eligible would have had significantly fewer comorbidities.14
The present study found of those older patients attending
routine primary care, fewer than 2% fulfilled the eligibility
criteria for HYVET, although those that were eligible had
comparable multimorbidity. Furthermore, our finding that
34.4% of older patients would have been eligible for the
SPRINT trial was very similar to that of Bress et al.,31 who
examined patients from the National Health and Nutrition
Examination Survey database and found 34.6% of patients
aged 75 and older would have been eligible for the trial.
The present study found that eligible populations dif-
fered significantly from those who participated in the original
trials. This accentuated the differences between eligible
patients and the general population. Participating patients
had higher blood pressure and BMI but fewer comorbidities.
Implications for Clinical Practices
Clinical guidelines for the management of hypertension in
older patients continue to recommend lower thresholds for
treatment initiation and targets for patients already on med-
ication.22,24,25 Most suggest exercising clinical judgment in
patients with multimorbidity and frailty,23,24 and some go
as far as to explicitly cite the exclusion criteria from the
SPRINT trial in reference to patients where such a strategy
may not be appropriate.25 The present data show the extent
to which clinical judgment may be required with as many
as two-thirds of patients aged older than 80 not meeting the
eligibility criteria for previous trials.
Further work is needed to better understand if differ-
ences between recruited trial participants and the general
population are important in determining the safety and effi-
cacy of treatments. Ultimately, it is not feasible to conduct
randomized controlled trials in all populations, but
attempts should be made to better capture patients from
underrepresented groups (such as those with frailty and
multimorbidity) in future trials. One approach might be to
consider the use of specific inclusion/exclusion criteria
designed to maximize the number of patients with frailty
and multimorbidity eligible.
In conclusion, the present study found that most patients
aged older than 80 would not have been eligible for large
randomized controlled trials examining hypertension man-
agement strategies in older adults, albeit mainly due to differ-
ing blood pressure control thresholds. Therefore, for many
older patients, no randomized controlled trials exist that
directly inform treatment decisions in routine practice, and
so caution should be exercised when using existing data in
older patients with frailty or multimorbidity.
ACKNOWLEDGMENTS
We acknowledge the support of the Primary Care Clinical
Trials Unit, staff from the National Institute for Health
Research Thames Valley and South Midlands and Wessex
Clinical Research Network, and all of the practices contrib-
uting data to this study.
Financial Disclosure: This work received joint funding
from the National Institute for Health Research (NIHR)
Oxford Collaboration for Leadership in Applied Health
Research and Care (CLAHRC) at Oxford Health National
Health Service (NHS) Foundation Trust (reference P2-501)
and the NIHR School for Primary Care Research (SPCR;
JAGS MONTH 2020-VOL. 00, NO. 00 GENERALIZABILITY OF BLOOD PRESSURE TRIALS 7
reference 335). James Sheppard and Richard J. McManus
were funded by an NIHR professorship (NIHR-RP-R2-
12-015). James Sheppard now receives funding from the
Wellcome Trust/Royal Society via a Sir Henry Dale Fellow-
ship (reference 211182/Z/18/Z) and an NIHR Oxford Bio-
medical Research Centre (BRC) Senior Fellowship. Richard
J. McManus, Jonathan Mant, Carl Heneghan, and Gary
A. Ford are supported by NIHR Senior Investigator awards.
Carl Heneghan also receives support from the NIHR SPCR
and NIHR Oxford BRC. F.D. Richard Hobbs acknowl-
edges part support from the NIHR SPCR, the NIHR
CLAHRC Oxford, and the NIHR Oxford BRC. Oliver
Todd is funded by a Dunhill Medical Trust doctoral
research fellowship (reference RTF107/0117). Rupert Payne
receives funding from the NIHR for polypharmacy and
medicines optimization research. The views expressed are
those of the author(s) and not necessarily those of the
NIHR or the Department of Health and Social Care.
Conflict of Interest: Gary A. Ford has received personal
payment for advisory and educational work from Amgen,
Daiichi Sankyo, Medtronic, Pfizer, and Stryker. All other
authors have declared no conflicts of interest for this article.
Author Contributions: Conceived, designed, and secured
funding for the study: Sheppard and McManus with Burt,
Lown, Ford, Heneghan, Hobbs, Jowett, Little, Mant, Payne,
Williams, and Yu. Study manager: Temple. Wrote the first
draft: Sheppard. All authors reviewed and edited the manu-
script. James Sheppard and Richard J. McManus are co-chief
investigators and will act as guarantors for this work.
Sponsor’s Role: The sponsor for this study (University
of Oxford) had no role in the design and conduct of the
study; collection, management, analysis, and interpretation
of the data; preparation, review, or approval of the manu-
script; and decision to submit the manuscript for publication.
REFERENCES
1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific rele-
vance of usual blood pressure to vascular mortality: a meta-analysis of indi-
vidual data for one million adults in 61 prospective studies. Lancet. 2002;
360(9349):1903-1913.
2. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention
of cardiovascular disease and death: a systematic review and meta-analysis.
Lancet. 2016;387(10022):957-967.
3. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in
patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.
4. SPRINT Investigators. A randomized trial of intensive versus standard
blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.
5. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment
of hypertension in patients 80 years and older: the lower the better? A
meta-analysis of randomized controlled trials. J Hypertens. 2010;28(7):
1366-1372.
6. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering
treatment on cardiovascular outcomes and mortality: 13 - benefits and
adverse events in older and younger patients with hypertension: overview,
meta-analyses and meta-regression analyses of randomized trials.
J Hypertens. 2018;36(8):1622-1636.
7. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious
fall injuries in a nationally representative sample of older adults. JAMA
Intern Med. 2014;174(4):588-595.
8. Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA. Prescrip-
tion of renin-angiotensin system blockers and risk of acute kidney injury: a
population-based cohort study. BMJ Open. 2016;6(12):e012690.
9. Benetos A, Labat C, Rossignol P, et al. Treatment with multiple blood pres-
sure medications, achieved blood pressure, and mortality in older nursing
home residents: the PARTAGE study. JAMA Intern Med. 2015;175(6):
989-995.
10. Todd OM, Wilkinson C, Hale M, et al. Is the association between blood
pressure and mortality in older adults different with frailty? A systematic
review and meta-analysis. Age Ageing. 2019;48(5):627-635.
11. Pajewski NM, Berlowitz DR, Bress AP, et al. Intensive vs standard blood pres-
sure control in adults 80 years or older: a secondary analysis of the systolic
blood pressure intervention trial. J Am Geriatr Soc. 2020;68(3):496-504.
12. Rothwell PM. External validity of randomised controlled trials: “to whom
do the results of this trial apply?”. Lancet. 2005;365(9453):82-93.
13. Supiano MA, Williamson JD. Applying the systolic blood pressure interven-
tion trial results to older adults. J Am Geriatr Soc. 2017;65(1):16-21.
14. Tulner LR, Kuper IM, van Campen JP, et al. Treatment of hypertension in
an elderly outpatient population in The Netherlands. Am J Geriatr
Pharmacother. 2009;7(4):204-209.
15. Pajewski NM, Williamson JD, Applegate WB, et al. Characterizing frailty
status in the systolic blood pressure intervention trial. J Gerontol A Biol Sci
Med Sci. 2016;71(5):649-655.
16. Kulminski A, Yashin A, Ukraintseva S, et al. Accumulation of health disor-
ders as a systemic measure of aging: findings from the NLTCS data. Mech
Ageing Dev. 2006;127(11):840-848.
17. Romero-Ortuno R, Kenny RA. The frailty index in Europeans: association
with age and mortality. Age Ageing. 2012;41(5):684-689.
18. Sheppard JP, Burt J, Lown M, et al. OPtimising Treatment for MIld Systolic
hypertension in the Elderly (OPTiMISE): protocol for a randomised con-
trolled non-inferiority trial. BMJ Open. 2018;8(9):e022930.
19. Bradley MC, Motterlini N, Padmanabhan S, et al. Potentially inappropriate
prescribing among older people in the United Kingdom. BMC Geriatr. 2014;
14:72.
20. Sato I, Akazawa M. Polypharmacy and adverse drug reactions in Japanese
elderly taking antihypertensives: a retrospective database study. Drug
Healthc Patient Saf. 2013;5:143-150.
21. Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data
in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;
338:b2393.
22. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/
AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the
prevention, detection, evaluation, and management of high blood pressure in
adults: a report of the American College of Cardiology/American Heart
Association Task Force on clinical practice guidelines. J Am Coll Cardiol.
2017;71(19):2199-2269.
23. National Guideline Centre. National Institute for Health and Care Excel-
lence. Hypertension in Adults: Diagnosis and Management [NICE Guideline
136]. London, UK: Royal College of Physicians; 2019.
24. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the
management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.
25. Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada’s 2018
guidelines for diagnosis, risk assessment, prevention, and treatment of hyper-
tension in adults and children. Can J Cardiol. 2018;34(5):506-525.
26. Public Health England. National General Practice Profiles. 2018. https://
fingertips.phe.org.uk/profile/general-practice. Accessed May 21, 2019.
27. Johnson KC, Whelton PK, Cushman WC, et al. Blood pressure measurement
in SPRINT (systolic blood pressure intervention trial). Hypertension. 2018;
71(5):848-857.
28. Clegg A, Bates C, Young J, et al. Development and validation of an elec-
tronic frailty index using routine primary care electronic health record data.
Age Ageing. 2016;45(3):353-360.
29. Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of
frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc.
2010;58(4):681-687.
30. Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty mod-
ifies the positive impact of antihypertensive treatment in very elderly people:
an investigation of the impact of frailty upon treatment effect in the HYper-
tension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-
controlled study of antihypertensives in people with hypertension aged
80 and over. BMC Med. 2015;13:78.
31. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Gen-
eralizability of SPRINT results to the U.S. adult population. J Am Coll Car-
diol. 2016;67(5):463-472.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
Supplementary Appendix S1: Supporting Information.
8 SHEPPARD ET AL. MONTH 2020-VOL. 00, NO. 00 JAGS
